Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age between 5-55 years (inclusive) of either gender.~* Newly diagnosed VL or VL treatment failure confirmed by spleen or bone marrow aspirate.~* Clinical signs and symptoms compatible with VL: fever of over two weeks duration and splenomegaly.~* Biochemical and haematological test values as follows:~  * Haemoglobin \> 5.0g/100mL~ * White blood cell count \> 1 x109/L~ * Platelet count \> 50 x 109/L~ * AST, ALT and alkaline phosphatase \< 3 times upper normal limit~ * Prothrombin time \< 5 seconds above control~ * Serum creatinine levels within normal limits~ * Serum potassium levels within normal limits~* HIV negative~Exclusion Criteria:~* A history of intercurrent or concurrent diseases (e.g. chronic alcohol consumption or drug addiction; renal, hepatic, cardiovascular or central nervous system disease; diabetes; tuberculosis or other infectious or major psychiatric diseases) that may introduce variables affecting the outcome of the study.~* Any condition which the investigator thinks may prevent the patient from completing the study therapy and subsequent follow-up.~* An abnormal baseline audiogram (presentation with 75 dB or higher at 8KHz or below) and/or a history of significant vestibular or auditory dysfunction.~* Proteinuria (\> 2+).~* A history of allergy or hypersensitivity to aminoglycosides.~* A history of major surgery within the last two weeks.~* Pregnancy or lactation. \[Note: women of childbearing age must use an adequate form of contraception (documented) or agree to a period of sexual abstinence during the treatment phase of the study.\]~* Previous treatment for VL within two weeks of enrolment into the study.~* Prior treatment failures with paromomycin or amphotericin B.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).